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Introduction. There is little information on the reasons for discontinuing inﬂiximab treatment in patients with Crohn’s disease.
The aim of this study was to document these reasons to determine if any were preventable which would allow patients to continue
the therapy. Aims & Methods. A review of the medical notes was conducted at the Norfolk and Norwich University Hospital on
patients with Crohn’s disease treated with inﬂiximab between 2002–2008 to determine the reasons for stopping it. Results.At o t a l
of 65 patients were identiﬁed who had treatment with inﬂiximab, of whom 23 (35.3%) had their therapy stopped. The reasons for
discontinuation of inﬂiximab in the 23 patients were: 47.8% side eﬀects, 17.4% refractory disease, 13.0% achieved remission and
did not receive long-term maintenance treatment, 4.34% pregnancy, 4.34% death, and unknown 13.0%. Conclusions. The main
reasons for the discontinuation of inﬂiximab were side eﬀects rather than a lack of clinical response.
1.Introduction
Severe Crohn’s disease is a debilitating illness which can have
a devastating impact on the quality of life of patients who
require life-long medication and frequently surgery. Patients
with severe refractory disease not responding to initial drug
treatment with 5-aminosalicylates and immunosuppressive
agents may require biological therapies. These drugs, includ-
ing inﬂiximab, a monoclonal antibody, inhibit the actions of
tumour necrosis factor alpha (TNF-α) whose concentration
is increased in the mucosa of patients with Crohn’s disease
[1]. Inﬂiximab currently induces and maintains clinical
remission in 30%–40% of all patients who are commenced
on therapy with intravenous infusions every eight weeks [2,
3]. Surprisingly, there is little information on why inﬂiximab
treatment is discontinued in patients and the subsequent
clinical outcomes. The possibilities include lack of eﬃcacy
of the drug, anaphylaxis, severe sideeﬀects and patients’
noncompliance. The purpose of this study was therefore to
identifythereasonsfordiscontinuationofinﬂiximabandthe
clinical outcome in such patients, treated at a large teaching
hospital. Identifying the reasons for discontinuation is
important to determine if any are preventable or treatable, so
that potentially more patients could beneﬁt from biological
therapies and achieve clinical remission.
2.Methodology
The study was conducted in patients with Crohn’s disease
treated at the Norfolk & Norwich University Hospital NHS
Trust, which serves a population of approximately half a mil-
lion people in the East of England. Patients were identiﬁed
from a database, in the Department of Gastroenterology,
who were treated with inﬂiximab between the years 2002–
2008. The database also included those patients who had
their treatment discontinued. Information was collected
on factors which aﬀect the clinical response to inﬂiximab
including smoking and the use of immunosuppressive drugs,2 ISRN Gastroenterology
namely, azathioprine and 6-mercaptopurine. The medical
case notes of all patients who had their inﬂiximab therapy
discontinued were reviewed by a gastroenterologist to obtain
information on demographic factors and the reasons for
discontinuation (including lack of clinical response, side
eﬀects, social reasons, and noncompliance) and the long-
term clinical outcomes.
3. Results
A total of 65 patients were treated with inﬂiximab at the
Norfolk and Norwich University Hospital between 2002
and 2008 of which 35.3% (n = 23) had their treatment
discontinued. In the nonresponders the median age at ﬁrst
infusion was 35 years (range = 18–74 years), 65.2% were
females, 60.7% of the patients (n = 14) were nonsmokers,
21.7% ex-smokers, and 17.4% continued to smoke. Crohn’s
disease was present at multiple sites in the gastrointestinal
tract in 78.3% (n = 18) patients and in only the terminal
ileum in 21.7% (n = 5). All patients had had a trial
of a thiopurine. The median number of infusions before
treatment discontinuation was 3 infusions (range = 1–20
infusions).
The reasons for discontinuation of inﬂiximab were:
47.8% (n = 11) side eﬀects, 17.4% (n = 4) refractory
disease, 13.0% (n = 3) achieved remission and did not
receive maintenance treatment (as recommended by initial
NICE guidance) [3], 4.5% (n = 1) pregnancy, 4.34%
(n = 1) death (Pneumocystis carinii pneumonia), and
13.0% (n = 3) were unknown. In the subgroup who had
side eﬀects, these were (expressed as % of number with
any side eﬀect): 36.4% (n = 4) with severe anaphylactic
reactions, 27.2% (n = 3) arthralgia, 9.0% (n = 1) acute
left ventricular failure, 9.0% (n = 1) cholestasis, 9.0%
(n = 1) hypertension with a systolic blood pressure over
200mmHg, and 9.0% (n = 1) recurrent headaches. Among
the subgroup with severe anaphylaxis (n = 4), one patient
developed shortness of breath, sweating, and rash during an
infusion 2 years after the commencement on inﬂiximab. The
second patient developed wheeze and became hypotensive
afterthesecondinfusion.Anotherpatientexperiencedsevere
headaches,rash,andfacialswellingninedaysafterthesecond
infusion. The fourth patient had paresthesia and diﬀused
rash while receiving the ﬁrst infusion. Overall the side eﬀects
led to discontinuation of treatment in 11 of the 65 (16.9%)
treated with inﬂiximab.
Theﬁnaloutcomesinthe23patientsinwhominﬂiximab
was discontinued were as follows: 11 patients (48%) under-
wentsurgery,3patientshadatotalcolectomy,2patientsloop
ileostomy, 1 proctectomy, 1 small bowel resection, 1 patient
had terminal ileal resection, 1 ileocaecal resection, 1 patient
drainage of ischiorectal abscess, and 1 repair of colovaginal
ﬁstula and subsequent hysterectomy. A further 22% of the 23
patients were maintained without further biological agents,
16% (n = 4) the outcome was unknown, 8% (n = 2) were
commenced on adalimumab, and 4% (n = 1) died.
4. Discussion
Long-term inﬂiximab treatment is beneﬁcial for approxi-
mately 60 percent of patients who initially respond, leading
to avoidance of hospital admissions and surgery [4]. In
our study, a third of patients commenced on inﬂiximab
had their treatment discontinued, and the main reasons for
this were side eﬀects, particularly anaphylactic reactions and
arthralgia. This emphasizes the importance of monitoring
patients for this eﬀect even if prophylaxis is given. More
researchisneededtodocumenttheprevalenceandtreatment
ofthearthropathyassociatedwithbiologicaltherapies.Three
patientshadthetreatmentstoppedafterachievingremission,
which is not current practice, but was the standard approach
at the time. However, NICE in their ﬁnal current approval
determination document state that biological therapies
should be given as a planned course or until treatment
failure, or 12 months after the start of the treatment,
whichever is the sooner [5]. Treatment with biological
therapies should be continued if there is clear evidence of
ongoing active disease as determined by symptoms, markers
of inﬂammation, and possibly endoscopy. This guidance has
been suggested in view of lack of information on the long-
term eﬃcacy of biological therapies and the severe but rare
complications of the treatment including hepatosplenic lym-
phoma and demyelination. Our work showed that those who
cannot receive long-term therapy need careful monitoring
as approximately half of them will require surgery later on.
Furthermore, clinicians are becoming more familiar with
prescribing alternative biological therapy if the ﬁrst fails. The
numbers studied were relatively small but gave an overview
of the potential limitations of inﬂiximab. The reasons for
discontinuation of biological therapies have been assessed
in other centres. A large observational, single-centre cohort
study from Leuven University Hospital, Belgium included
614 patients with Crohn’s disease who were treated with
inﬂiximab. In 11% (70/614) of patients, the treatment was
discontinued because of side eﬀects after a median of ﬁve
infusions. These included acute infusion reactions in 2.4%
(15/614) of patients and delayed infusion reactions in 5.3%
(33/614) of patients. Serious infections were diagnosed in
0.8% (5/614) of patients including herpes zoster, abdominal
tuberculosis, and Aspergillus infection. Three patients had
to stop inﬂiximab because of neurological complications
(one patient with possible neuritis optica, one patient with a
diagnosed central demyelinating lesion, and one patient with
extensive multiple sclerosis-like neurological symptoms) [4].
In summary a third of patients in our study were not
able to continue long-term treatment with inﬂiximab. More
p a t i e n t sm a yb ea b l et oc o n t i n u ei fs i d ee ﬀects of treatment
can be better understood, prevented, and managed. Long-
term followup of those whose treatment was discontinued
is important as many may need surgery or an alternative
biological therapy.
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